Lead Product(s) : Fleroxacin
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The 26-week blinded phase 2 monotherapy trial with AM833 investigated safety, tolerability and efficacy for weight management in 706 people with obesity or overweight with at least one weight-related comorbidity.
Brand Name : AM833
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
June 18, 2020
Lead Product(s) : Fleroxacin
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?